Biomarker study of a multicentre, open-label, randomized Phase III Study of Atezolizumab with Platinum-Pemetrexed with or without Bevacizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer WJOG11218L/APPLE (APPLE Biomarker study) (WJOG11218LTR)

Biomarker study of a multicentre, open-label, randomized Phase III Study of Atezolizumab with Platinum-Pemetrexed with or without Bevacizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer WJOG11218L/APPLE (APPLE Biomarker study) (WJOG11218LTR) - Apple biomarker study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037326

Enrollment

200

Registered

2019-07-10

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced non-squamous non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who agreed by consent forms to attend this study among those who attended WJOG 11218L.

Exclusion criteria

Exclusion criteria: Subjects who do not agree by consent forms to attend this study.

Design outcomes

Primary

Measure	Time frame
Exploration of biomarkers to predict response to platinum-combined immunotherapies	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results